Skip to main content
Publications
Zografos LJ , Andrews EB, Wolin DL , Calingaert B , Davenport EK , Hollis KA , Petraro P, Djokanovic N, Racanelli VS, Vassilev Z. Evaluating physician knowledge of safety information for aflibercept (Eylea) . Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):592. doi: 10.1002/pds
Balp M, Abuzakouk M, Berard F, Canonica GW, Gimenez-Arnau A, Hollis K , Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Maurer M, McBride D, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Grattan C. Comparison of direct healthcare costs associated with chronic spontaneous/idiopathic urticaria in 7 countries - results from the ASSURE-CSU study . Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A565.
Hollis K , Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Khalil S, Knulst AC, Lacour J, Lynde C, Maurer M, McBride D, Nakonechna A, Ortiz De Frutos J, Oude Elberink J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Marsland A. Assessing health-utility values for chronic spontaneous/idiopathic urticaria in real-world using the EQ-5D: results from ASSURE-CSU study . Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A570-1.
McBride D, Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K , Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Maurer M. Comparative analysis of indirect costs associated with chronic spontaneous/idiopathicurticaria-results from the ASSURE-CSU study in 7 countries . Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A573.
Zografos LJ , Suzart K, Horvat-Broecker A, Soriano-Gabarro M, Wolin DL , Calingaer B , Davenport EK , Hollis KA , Andrews E. Evaluating physician knowledge of risks and safe use of Xarelto (rivaroxaban) . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):288-9.
McBride D, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K , Khalil S, Knulst A, Lacour J-P, Lynde C, Marsland A, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink JNG, Proctor C, Sussman G, Weller K, Maurer M. ASSURE-CSU: assessing the impact of chronic spontaneous/idiopathic urticaria on work productivity and activity . Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A124-5.
White MV, Silvia S, Hollis K , Wooddell M, Goss D , Odom D , Cooney D, Bartsch J , Hogue S. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events . Poster presented at the 2016 AAAAI Annual Meeting; March 4, 2016. Los Angeles, CA. [abstract] J Allergy Clin Immunol. 2016; 137:AB52.
Sussman G, Lynde C, Zanganeh S, Lacuesta G, Chiva-Razavi S, Chambenoit O, Khalil S, Hollis KA , McBride DW, Westlund RE, Sweeney CT , Tian H, Balp MM. ASSURE-CSU preliminary Canadian results: an analysis of the diagnosis and treatment of patients with antihistamine-refractory CSU . Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada. [abstract] Clin Transl Allergy. 2015 Aug 17; 5(29):1-7. doi: 10.1186/s13601-015-0072-9
Hogue SL, Bennett ME, Goss DS , Hollis KA , Millar K, Silvia S, Siegel P, Wolf R, Wooddell M, White MV. Availability and use of epinephrine auto-injectors for the treatment of anaphylaxis: results from the EpiPen4Schools® survey . Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A178. doi: 10.1016/j.jval.2015.03.1030
Wooddell M, Goss DS , Hollis KA , Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Hogue SL, White MV. Epinephrine administration for cases of anaphylaxis in a US school setting: results from the EpiPen4Schools survey . Poster presented at the 2015 AAAAI Annual Meeting; February 20, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(2):AB212.
White MV, Goss D , Hollis K , Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue S. EpiPen4Schools® survey: characteristics of anaphylaxis and common triggers . Poster presented at the 2015 AAAAI Annual Meeting; February 15, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(Suppl 2):AB212.
Hogue SL, Bennett ME, Goss DS , Hollis KA , Millar K, Silvia S, Siegel P, Wolf RA, Wooddell M, White MV. Occurrence of anaphylaxis by school grade level and staff training: findings from the EpiPen4Schools survey . Poster presented at the 2015 AAAAI Annual Meeting; February 23, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135(2):AB212.
White MV, Goss DS , Hollis KA , Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue SL. EpiPen4Schools survey: characteristics of anaphylaxis and common triggers . Poster presented at the 2015 AAAAI Annual Meeting; February 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135:AB212.